Study of the effectiveness of interferon gamma therapy and evaluation of its effect on the level of cytokines in patients with chronic polypous rhinosinusitis

Cover Page

Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access


Background. Chronic polyposis rhinosinusitis is characterized by an immune-dependent type of polyp formation with a defect in local protective factors. The use of local immunomodulators will improve immune protection in the nasal cavity.

Aim. To study cytokine levels in nasal secretion and blood serum in patients with chronic polyposis rhinosinusitis after therapy with interferon gamma.

Material and methods. To study immunological indices, 32 patients with chronic polyposis rhinosinusitis, who were treated with intranasal interferon gamma, and 30 healthy people (control group) were examined. In the group of patients with the disease, the levels of interleukins-4, -10 and -18, tumor necrosis factor α, and secretory immunoglobulin A were determined in the nasal secretion and blood serum before treatment and 1 month after it. Statistical analysis of the results was performed using the Statistica 12.0 software package. The test for normality of distribution in the sample was carried out using the Shapiro–Wilk test. Most of the parameters did not have a normal distribution; therefore, nonparametric statistical methods were used for further analysis. The description of the results obtained in the study was carried out by calculating the median (Me) and the interquantile range in the form of the 25th and 75th percentiles (Q0.25 and Q0.75). Comparative analysis of quantitative signs in independent groups was performed according to the Mann–Whitney test, in dependent groups — using the Wilcoxon method. Differences were considered significant at p <0.05.

Results. Clinical efficacy was assessed according to a 4-point scale: excellent treatment result, good result, satisfactory and unsatisfactory. A good effect of the therapy was 78.1% (25 patients). Unsatisfactory effect was registered in 7 (21.9%) patients. After treatment, a decrease in the content of interleukin-4 (p2=0.000034), interleukin-18 (p2=0.000075), an increase in the level of interleukin-10 (p2=0.033), a decrease in the amount of secretory immunoglobulin A in the nasal secretion (p2=0.0001) took place. The levels of tumor necrosis factor α in blood serum were reduced both before treatment compared with the control group (p1=0.005) and after therapy (p2=0.000075).

Conclusion. An increase in the content of interleukin-10 in the nasal secretion and a decrease in the level of proinflammatory cytokines — interleukin-18, tumor necrosis factor α and interleukin-4 — in the blood serum after treatment with interferon gamma in patients with chronic polyposis rhinosinusitis may indicate a decrease in the activity of immune inflammation in the nasal cavity.

Full Text

Restricted Access

About the authors

Nadezhda I. Baranova

Penza Institute for Postgraduate Medical Education, branch of the Russian Medical Academy of Continuing Professional Education

ORCID iD: 0000-0002-2991-0898

D. Sci. (Biol.), Prof., Head, Central Research Laboratory

Russian Federation, Penza, Russia

Lyudmila A. Ashchina

Penza Institute for Postgraduate Medical Education, branch of the Russian Medical Academy of Continuing Professional Education

Author for correspondence.
ORCID iD: 0000-0002-4445-5619

Cand. Sci. (Biol.), Senior Researcher, Central Research Laboratory

Russian Federation, Penza, Russia

Natalia A. Shkurova

Penza Institute for Postgraduate Medical Education, branch of the Russian Medical Academy of Continuing Professional Education; Clinical Hospital No. 6 named after G.A. Zakharyin

ORCID iD: 0000-0003-0434-1972

M.D.; Assistant, Depart. of Otorhinolaryngology and Surdology-Otorhinolaryngology

Russian Federation, Penza, Russia; Penza, Russia

Boris A. Molotilov

Penza Institute for Postgraduate Medical Education, branch of the Russian Medical Academy of Continuing Professional Education

ORCID iD: 0000-0003-4129-2815

M.D., D. Sci. (Med.), Prof., Head of Depart., Depart. of Allergology and Immunology

Russian Federation, Penza, Russia


  1. Xu M, Chen D, Zhou H, Zhang W, Xu J, Chen L. The role of periostin in the occurrence and progression of eosi¬nophilic chronic sinusitis with nasal polyps. Sci Rep. 2017;7(1):9479. doi: 10.1038/s41598-017-08375-2.
  2. McCormick JP, Thompson HM, Cho DY, Woodworth BA, Grayson JW. Phenotypes in chronic rhinosinusitis. Curr Allergy Asthma Rep. 2020;20(7):20. doi: 10.1007/s11882-020-00916-6.
  3. Mokronosova MA. Triggering factors of chronic rhinosinusitis with nasal polyposis. Russian journal of allergy. 2011;(1):25–31. (In Russ.)
  4. Savlevich EL, Kurbacheva OM, Egorov VI, Dyneva ME, Shilovskiy IP, Khaitov MR. Gene expression levels of cytokines in different phenotypes of CRSwNP. Vestnik otorinolaringologii. 2019;84(6):42–47. (In Russ.) doi: 10.17116/otorino20198406142.
  5. Koennecke M, Klimek L, Mulloj J, Gevaert P, Wollenberg B. Subtyping of polyposis nasi: phenotypes, endotypes and comorbidities. Allergo J Int. 2018;27(2):56–65. doi: 10.1007/s40629-017-0048-5.
  6. Kozlov VS, Savlevich EL. Chro¬nic rhinosinusitis with nasal polyps. The recent trend in the studies of the pathogenesis, diagnosis and treatment of this disease. Vestnik otorinolaringologii. 2015;(4):95–99. (In Russ.) doi: 10.17116/otorino201580495-99.
  7. Brescia G, Zanotti C, Parrino D, Barion U, Mario¬ni G. Nasal polyposis pathophysiology: Endotype and phenotype open issues. Am J Otolaringol. 2018;39(4):441–444. doi: 10.1016/j.amjoto.2018.03.020.
  8. Koennecke M, Böscke R, Pfannerstill AC, Reers S, Elsner M, Fell B, Richter A, Bruchhage KL, Schumann S, Pries R. Neuronal differentiation capability of nasal polips of chronic rhinosinusitis. Arch Immunol Ther Exp. 2017;65(5):431–443.doi: 10.1007/s00005-017-0456-8.
  9. Krivopalov AA. Rhinosinusitis: Definitions, classifications, etiology and epidemiology (А review of literature). Rossiyskaya rinologiya. 2016;24(2):39–45. (In Russ.) doi: 10.17116/rosrino201624239-45.
  10. Ryazantsev SV, Budkovaya MA. Current view of the treatment of chronic rhinosinusitis with nasal polyps. Rossiyskaya rinologiya. 2017;25(1):54–59. (In Russ.) doi: 10.17116/rosrino201725154-59.
  11. Savlevich EL, Kurbacheva OM, Shachnev KN. The expediency of the application of the immunomodulatory medications for the treatment of chronic rhinosinusitis with nasal polyps. Rossiyskaya rinologiya. 2018;26(3):41–46. (In Russ.) doi: 10.17116/rosrino20182603141.
  12. Gevaert P, Omachi TA, Corren J, Mullol J, Han J, Lee SE. Efficacy and safety of omalizumab in nasal poly¬posis: 2 randomized phase 3 trials. J Allergy Clin Immunol. 2020;146(3):595–605. doi: 10.1016/j.jaci.2020.05.032.
  13. Stagnieva IV, Simbirtsev AS. Immunotherapy efficiency in rhinosinusitis patients. Meditsinskaya immunologiya. 2015;17(5):423–430. (In Russ.) doi: 10.15789/1563-0625-2015-5-423-430.
  14. Kuznetsova LV, Babadzhan VD, Kravchun PG, Elizarova TA, Shulyak MA, Sheykh Sadzhade Mokhammad Reza, Piletskiy AM., Litus VI, Nazarenko AP, Romanyuk LI, Bezdetko TV, Zaykov SV, Kurchenko AI, Osipova LS, Khomenko IM, Nazar OV, Kuznetsov AG, Bondarenko TN. Sovremennye predstavleniya ob etiologii i patogeneze polipoznykh rinosinusitov, protekayushchikh na fone kruglogodichnogo allergicheskogo rinita. (Modern ideas about the etio¬logy and pathogenesis of polypous rhinosinusitis occurring against the background of year-round allergic rhinitis.) Kiev: Aktavis Ukraina; 2015. 94 p. (In Russ.)
  15. Bohman A, Oscarsson M, Holmberg K, Johansson L, Millqvist E, Nasic S, Bende M. Relative frequencies of symptoms and risk factors among patients with chro¬nic rhinosinusitis with nasal polyps using a case-control study. Acta Otolaryngol. 2018;138(1):46–49. doi: 10.1080/00016489.2017.1366052.
  16. Sepiashvili RI. From immunotherapy to personalized targeted immunomodulatory therapy and immunorehabilitation. Allergologiya i immunologiya. 2015;16(4):323–327. (In Russ.)
  17. Emelina YuN, Zurochka AV. Cytokine profile of nasal secretions in children with combined forms of pollinosis. Tsitokiny i vospalenie. 2016;15(1):81–85. (In Russ.)
  18. Simbirtsev AS. Sitokiny v patogeneze i lechenii zabolevaniy cheloveka. (Cytokines in the pathogenesis and treatment of human diseases.) SPb.: Foliant. 2018. 512 p. (In Russ.)

Supplementary files

There are no supplementary files to display.

© 2022 Eco-Vector

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies